Piramal Enterprises Limited (PEL.NS)
INR 978.0
(1.04%)
INR 978.0
(1.04%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.86 Billion INR | -127.13% |
| 2022 | 46.08 Billion INR | -42.23% |
| 2021 | 73.37 Billion INR | 0.95% |
| 2020 | 74.89 Billion INR | 10.93% |
| 2019 | 84.44 Billion INR | -2.31% |
| 2018 | 72.66 Billion INR | 36.64% |
| 2017 | 52.07 Billion INR | 38.42% |
| 2016 | 35.48 Billion INR | 82.03% |
| 2015 | 21.63 Billion INR | 94.21% |
| 2014 | 8.89 Billion INR | 78.55% |
| 2013 | 6.2 Billion INR | 16.66% |
| 2012 | 4.45 Billion INR | 275.16% |
| 2011 | -361.6 Million INR | -75.22% |
| 2010 | 1.22 Billion INR | -28.48% |
| 2009 | 7.26 Billion INR | -47.88% |
| 2008 | 5.88 Billion INR | 153.93% |
| 2007 | 5.19 Billion INR | 11.05% |
| 2006 | 3.88 Billion INR | 125.31% |
| 2005 | 2.37 Billion INR | 17.21% |
| 2004 | 2.02 Billion INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 15.5 Billion INR | 616.31% |
| 2024 Q1 | -3 Billion INR | 83.43% |
| 2023 Q1 | 32.36 Billion INR | 2670.72% |
| 2023 FY | - INR | -127.13% |
| 2023 Q3 | 13.48 Billion INR | 12.35% |
| 2023 Q2 | 12 Billion INR | -62.91% |
| 2023 Q4 | -18.12 Billion INR | -234.37% |
| 2022 Q3 | 16.61 Billion INR | 187.03% |
| 2022 FY | - INR | -42.23% |
| 2022 Q1 | 21.03 Billion INR | 12.05% |
| 2022 Q2 | 5.78 Billion INR | -72.49% |
| 2022 Q4 | 1.16 Billion INR | -92.97% |
| 2021 FY | - INR | 0.95% |
| 2021 Q3 | 25.97 Billion INR | 49.81% |
| 2021 Q1 | 18.18 Billion INR | 7.13% |
| 2021 Q4 | 18.77 Billion INR | -27.71% |
| 2021 Q2 | 17.33 Billion INR | -4.65% |
| 2020 Q4 | 16.97 Billion INR | -20.94% |
| 2020 FY | - INR | 10.93% |
| 2020 Q1 | 18.95 Billion INR | 915.17% |
| 2020 Q2 | 20.87 Billion INR | 10.12% |
| 2020 Q3 | 21.46 Billion INR | 2.82% |
| 2019 Q3 | 25.62 Billion INR | 6.23% |
| 2019 FY | - INR | -2.31% |
| 2019 Q2 | 24.12 Billion INR | 7.44% |
| 2019 Q4 | -2.32 Billion INR | -109.07% |
| 2019 Q1 | 22.45 Billion INR | 17.48% |
| 2018 FY | - INR | 36.64% |
| 2018 Q2 | 17.09 Billion INR | 10.92% |
| 2018 Q1 | 15.41 Billion INR | 8.73% |
| 2018 Q4 | 19.11 Billion INR | -10.26% |
| 2018 Q3 | 21.3 Billion INR | 24.61% |
| 2017 FY | - INR | 38.42% |
| 2017 Q4 | 14.17 Billion INR | -6.21% |
| 2017 Q3 | 15.11 Billion INR | 12.33% |
| 2017 Q2 | 13.45 Billion INR | 17.43% |
| 2017 Q1 | 11.45 Billion INR | 2.41% |
| 2016 FY | - INR | 82.03% |
| 2016 Q4 | 11.18 Billion INR | -1.62% |
| 2016 Q3 | 11.37 Billion INR | 44.67% |
| 2016 Q2 | 7.85 Billion INR | 13.72% |
| 2016 Q1 | 6.91 Billion INR | 45.27% |
| 2015 Q4 | 4.75 Billion INR | -27.83% |
| 2015 Q1 | 4.21 Billion INR | 93.23% |
| 2015 Q2 | 5.26 Billion INR | 24.92% |
| 2015 Q3 | 6.59 Billion INR | 25.12% |
| 2015 FY | - INR | 94.21% |
| 2014 Q1 | 2.56 Billion INR | 232.77% |
| 2014 Q4 | 2.18 Billion INR | -48.34% |
| 2014 Q2 | 2.27 Billion INR | -11.1% |
| 2014 FY | - INR | 78.55% |
| 2014 Q3 | 4.22 Billion INR | 85.35% |
| 2013 Q1 | 2.6 Billion INR | 1386.23% |
| 2013 FY | - INR | 16.66% |
| 2013 Q4 | -1.93 Billion INR | -165.31% |
| 2013 Q3 | 2.95 Billion INR | 19.19% |
| 2013 Q2 | 2.48 Billion INR | -4.6% |
| 2012 Q4 | 175 Million INR | -93.47% |
| 2012 Q2 | 1.01 Billion INR | -25.01% |
| 2012 Q1 | 1.35 Billion INR | 174.79% |
| 2012 Q3 | 2.68 Billion INR | 163.01% |
| 2012 FY | - INR | 275.16% |
| 2011 Q3 | 366.9 Million INR | 0.0% |
| 2011 FY | - INR | -75.22% |
| 2011 Q4 | -1.81 Billion INR | -595.45% |
| 2010 FY | - INR | -28.48% |
| 2009 FY | - INR | -47.88% |
| 2008 FY | - INR | 153.93% |
| 2007 FY | - INR | 11.05% |
| 2006 FY | - INR | 125.31% |
| 2005 FY | - INR | 17.21% |
| 2004 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Amrutanjan Health Care Limited | 681.59 Million INR | 666.479% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | 29809.911% |
| Caplin Point Laboratories Limited | 6.18 Billion INR | 162.439% |
| FDC Limited | 3.38 Billion INR | 214.052% |
| Gufic Biosciences Limited | 1.48 Billion INR | 360.799% |
| Hikal Limited | 2.69 Billion INR | 243.416% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 156.271% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 248.128% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | 1443.342% |
| Medico Remedies Limited | 129.09 Million INR | 3090.921% |
| Nectar Lifesciences Limited | 1.53 Billion INR | 351.441% |
| Par Drugs and Chemicals Limited | 228.17 Million INR | 1792.174% |
| RPG Life Sciences Limited | 1.28 Billion INR | 401.295% |
| Sequent Scientific Limited | 549.8 Million INR | 802.274% |
| Shilpa Medicare Limited | 2.58 Billion INR | 249.193% |
| Sigachi Industries Limited | 883.39 Million INR | 537.074% |
| Themis Medicare Limited | 562.6 Million INR | 786.287% |
| Unichem Laboratories Limited | 742.35 Million INR | 620.114% |
| Venus Remedies Limited | 711.8 Million INR | 642.441% |
| Wanbury Limited | 985.49 Million INR | 491.795% |
| ZIM Laboratories Limited | 462.09 Million INR | 935.56% |
| Lupin Limited | 36.96 Billion INR | 110.444% |
| Innova Captab Limited | 1.66 Billion INR | 331.438% |
| Ind-Swift Limited | 1.06 Billion INR | 462.522% |
| Bajaj HealthCare Limited | 406.23 Million INR | 1050.453% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 106.249% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | -36.826% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 263.828% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | 2307.024% |
| Morepen Laboratories Limited | 1.72 Billion INR | 323.708% |
| Laurus Labs Limited | 8 Billion INR | 148.228% |
| Aarti Drugs Limited | 3.24 Billion INR | 218.853% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 156.261% |
| Alembic Limited | 1.11 Billion INR | 445.871% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 140.15% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 134.037% |
| Vaishali Pharma Limited | 31.71 Million INR | 12275.901% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 198.764% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | 1293.687% |
| Jubilant Pharmova Limited | 8 Billion INR | 148.228% |
| Eris Lifesciences Limited | 6.98 Billion INR | 155.266% |
| Windlas Biotech Limited | 781.72 Million INR | 593.924% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 102.791% |
| Lincoln Pharmaceuticals Limited | 1.34 Billion INR | 387.429% |
| Orchid Pharma Limited | 1.41 Billion INR | 372.066% |
| Albert David Limited | 1.04 Billion INR | 469.334% |
| Hester Biosciences Limited | 539.47 Million INR | 815.721% |
| Sakar Healthcare Limited | 393.26 Million INR | 1081.799% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 182.552% |
| Procter & Gamble Health Limited | 3.07 Billion INR | 225.589% |
| Divi's Laboratories Limited | 25.43 Billion INR | 115.183% |
| Mankind Pharma Limited | 28.09 Billion INR | 113.743% |
| Neuland Laboratories Limited | 4.74 Billion INR | 181.317% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 141.362% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 106.868% |
| Wockhardt Limited | 1.08 Billion INR | 457.509% |
| Bal Pharma Limited | 345.59 Million INR | 1217.242% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 104.374% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 361.056% |
| Alkem Laboratories Limited | 24.19 Billion INR | 115.958% |
| Valiant Laboratories Limited | 12.73 Million INR | 30409.286% |
| Ajanta Pharma Limited | 12.56 Billion INR | 130.728% |
| Bafna Pharmaceuticals Limited | 114.58 Million INR | 3469.697% |
| Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | 8648.876% |
| Granules India Limited | 8.6 Billion INR | 144.877% |
| Medicamen Biotech Limited | 245.66 Million INR | 1671.725% |
| Ipca Laboratories Limited | 13.29 Billion INR | 129.032% |
| Brooks Laboratories Limited | 41.72 Million INR | 9353.02% |
| Syncom Formulations (India) Limited | 430.27 Million INR | 997.354% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 111.029% |
| NATCO Pharma Limited | 18.79 Billion INR | 120.543% |
| Suven Life Sciences Limited | -992.78 Million INR | -288.918% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | -4567.279% |
| Strides Pharma Science Limited | 3.76 Billion INR | 202.561% |
| Indoco Remedies Limited | 2.64 Billion INR | 245.864% |
| Alpa Laboratories Limited | 229.96 Million INR | 1779.024% |
| Lasa Supergenerics Limited | -65.08 Million INR | -5832.852% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | -3.474% |